Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a non-binding Letter of Intent ("LOI") with Ifowonco Informatics Incorporated ("Ifowonco") as an initial step toward negotiating a definitive agreement that would, if completed, grant Onco an exclusive option relating to Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 ("LAG-3") (the "LAG-3 Program"). The proposed collaboration is intended to combine Ifowonco's novel oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DNA damage response (DDR) therapeutics, translational oncology and clinical development.

Calgary, Canada – August 12, 2026 – TheNewswire - Onco-Innovations Limited (CBOE CA: ONCO ) (OTCQB: ONNVF ) (Frankfurt: W1H , WKN: A3EKSZ ) (" Onco " or the " Company ”) is pleased to announce, further to its news release dated July 30, 2026, that Nanosoft Polymers ("Nanosoft") has identified a non-tin catalyst for use in the continued development of the polymer synthesis process supporting ONC010, the Company's lead nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase ("PNKP"). The identification builds on previously announced catalyst-evaluation activities aimed at improving the consistency and reproducibility of the polymer used in ONC010's nanoparticle formulation. The non-tin approach is expected to support the Company's strategy for controlling catalyst-related impurities and developing a well-characterized polymer manufacturing process suitable for future GMP manufacturing. Nanosoft will continue to evaluate the catalyst as part of the ongoing polymer development program.